Zylox-Tonbridge Medical Technology Co., Ltd. (ZYLOXTB) disclosed a repurchase of 55,500 H-shares on 17 September 2026, conducted on the Hong Kong Stock Exchange under its existing buyback mandate approved on 13 May 2026.

The transaction was executed within a price range of HKD 20.52 to HKD 21.12 per share, translating into an aggregate consideration of HKD 1.15 million. The volume-weighted average repurchase price stood at roughly HKD 20.70 (RMB 20.7034), and the shares were retained as treasury stock.

Post-transaction, Zylox-Tonbridge’s issued share capital (excluding treasury shares) decreased by 0.0168 % to 322.71 million shares, while treasury shares increased to 13.64 million. The company’s total issued shares remain unchanged at 336.35 million, as the repurchased shares have not yet been cancelled.

Since receiving shareholder authorisation to buy back up to 32.72 million shares, the company has repurchased 4.74 million shares, representing 1.42 % of the share base approved under the mandate. In line with Hong Kong listing regulations, Zylox-Tonbridge is now subject to a moratorium on issuing new shares or disposing of treasury shares until 17 October 2026.